Sorin Group

BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent  

Retrieved on: 
금요일, 5월 3, 2024
Science, Sorin Group, Rowan University, University, GXP, Organization, Pharmacy, Blood, Laboratory, Safety, Hospital, Supreme court, Whittier Law School, University of Pittsburgh, Bankruptcy, Johnson & Johnson, Business administration, United States district court, Supreme, MLAB, District court, Biosensors International, Wilfrid Laurier University, UCC, La Salle College, Brownstein Hyatt Farber Schreck, St. Jude Medical, University of Chicago, Boston Scientific, Management

The final compositions of the committees to the Board will be determined in the very near term.

Key Points: 
  • The final compositions of the committees to the Board will be determined in the very near term.
  • The Board is now compliant with the rules and regulations that govern the standards acceptable to major U.S.
  • Mr. Amato has hands-on executive skills at engaging and influencing key stakeholders to not only grow business but also to optimize profits.
  • Mr. Amato founded InQuest Science in March 2017 and then acquired Bridge Associates International Pharmaceutical Consulting in March 2020.

LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023

Retrieved on: 
목요일, 9월 21, 2023
Cardiology, Sports, Biotechnology, Health, Mental Health, Health Technology, Medical Devices, Research, Hospitals, Surgery, Science, Interim, PLC, LIVN, Head, CP, Poletti, Hope, LivaNova, Retirement, Patient, Neuromodulation, Dolci, Chairperson, Knowledge, Small Business Saturday, Sorin Group, Management

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December 31, 2023.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December 31, 2023.
  • Dolci will continue in his role and support the transition of responsibilities through the end of the year.
  • LivaNova will retain a leading international executive search firm to assist with the search for a permanent successor for the President of CP.
  • “We wish Marco the best in his retirement from LivaNova.

Catalyst Advisors LP Appoints New Director to Support European Expansion

Retrieved on: 
화요일, 7월 26, 2022
Professional Services, Business, Other Science, Consulting, Science, Outsourcing Business, Master of Management: Co-operatives and Credit Unions, Sorin Group, Health care, University, Cyberon, Industry, Corporate title, Health, AJ, LivaNova, EMEA, Organization, Business development, Science, Management, Growth, PLC, Pharmaceutical industry, F500

Catalyst Advisors LP, an international executive recruitment and assessment firm singularly focused on life sciences, announced today the appointment of new Director, Andrew (AJ) MacBride Brown.

Key Points: 
  • Catalyst Advisors LP, an international executive recruitment and assessment firm singularly focused on life sciences, announced today the appointment of new Director, Andrew (AJ) MacBride Brown.
  • I am honored to join Catalyst Advisors and partner with team members equally committed to supporting companies at the frontier of science as they work toward meeting complex patient needs, said AJ MacBride Brown, Director at Catalyst Advisors.
  • With the shift to remote and hybrid working models, cross-border recruitments have dramatically increased in the post-pandemic era.
  • Catalyst Advisors is a global executive recruiting firm that is singularly focused on connecting visionary leaders with life sciences organizations at all stages of growth.

Global Nasal Cannula Market to 2028 - Size, Share, Outlook and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
수요일, 2월 16, 2022
Health, Medical Supplies, Medical Devices, Well, Asthma, Silicon, GSK, Degenerative disease, Patient, COVID, Sorin Group, Lung cancer, European Respiratory Society, Vaccine, Infection, Urgent, Awareness, Therapy, US, AstraZeneca, Chronic obstructive pulmonary disease, Pulmonary fibrosis, Vir, Pneumonia, Biotechnology, Marketing, COPD, Oxygen, Industry, Medtronic, Growth, Research, Coronavirus, Forum of International Respiratory Societies, COVID-19, News, Program, CAGR, Pharmaceutical industry

The "The Nasal Cannula Market - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Nasal Cannula Market - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • These nasal cannula tubes are available at a low cost, which drives the growth of the nasal cannula market.
  • This is expected to increase the growth of the global nasal cannula market over the forecast period.
  • Increasing awareness for the treatment as well as management of respiratory diseases is expected to increase the growth of the global nasal cannula market over the forecast period.